‘Naming and Framing’: The impact of labelling on health state values for multiple sclerosis by Green, C et al.
1 
 
 
(Running Head: The impact of labelling on health state values) 
 
 
Title:  ‘Naming and Framing’: The impact of labelling on health state 
values for multiple sclerosis 
 
 
Colin Green (PhD) 1,2 *, Elizabeth Goodwin (PhD) 1, Annie Hawton (PhD) 1,2 
 
1 Health Economics Group, University of Exeter, Exeter, UK, EX1 2LU 
2 South West Collaboration for Leadership in Applied Health Research and Care (CLAHRC), 
University of Exeter Medical School, University of Exeter, Exeter, UK, EX1 2LU 
 
 
 
* Corresponding Author:  Colin Green, University of Exeter, St Luke’s Campus, South Cloisters, 
Exeter, EX1 2LU.  Email: c.green@exeter.ac.uk 
 
 
 
Word-count total for the manuscript text = 4,300 (excluding the abstract, acknowledgments, 
references, and figure legends). 
 
 
 
 
Financial Statement:  Financial support for this study was provided in part by the Multiple 
Sclerosis Society of Great Britain and Northern Ireland.  The funding agreement ensured the 
authors’ independence in designing the study, interpreting the data, writing, and publishing 
the report.  C Green and A Hawton acknowledge partial funding from the UK NIHR 
Collaboration for Leadership in Applied Health Research and Care of the South West 
Peninsula (PenCLAHRC). The views expressed in this publication are those of the authors 
and not necessarily those of the Multiple Sclerosis Society, the UK NIHR or the Department 
of Health. 
 
2 
 
Abstract 
Introduction:  Health state valuation is a key input to many economic evaluations that 
inform resource allocation across competing health care interventions. Empirical evidence 
has shown that respondents to preference elicitation surveys may value a health state 
differently if aware of the condition causing it (‘labelling effects’).  This study investigates the 
impact of including a multiple sclerosis (MS) label for valuation of MS health states. 
Methods:  Health state values for MS were elicited using two internet-based surveys in 
representative samples of the UK population (n=1702; n=1788).  In one survey respondents 
were not informed that health states were caused by MS.  The second survey included a 
condition label for MS.  Surveys were identical in all other ways.  Health states were 
described using a MS-specific eight-dimensional classification system (MSIS-8D), and the 
time trade-off valuation technique was used.  Differences between values for labelled and 
unlabelled states are assessed using descriptive statistics and multivariate regression 
methods.   
Results:  Adding a MS condition label had a statistically significant effect on mean health 
state values, resulting in lower values for labelled MS states versus unlabelled states.  Data 
suggests the MS label had a more significant effect on values for less severe states, and no 
significant effect on values for the most severe states.  The inclusion of the MS label had a 
differential impact across the dimensions of the MSIS-8D.  Across the MSIS-8D, predicted 
values ranged from 0.079-0.883 for unlabelled states, and 0.066-0.861 for labelled states.  
Conclusions:  Differences reported in health state values, using labelled and unlabelled 
states, demonstrate that condition labels affect the results of valuation studies, and can have 
important implications in decision-analytic modelling and in economic evaluations.   
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1. Introduction 
Economic evaluations in the health care setting commonly employ quality-adjusted life-years 
(QALYs), within cost-utility analyses, to inform decisions on the reimbursement of health 
care interventions.  The basic QALY construct is that individuals experience different health 
states over time and that each health state has a value attached to it, with QALYs used to 
represent the value-weighted (quality-adjusted) accumulated time e.g. life-years1.  Health 
state values (HSVs) are on a scale where the value of being dead is zero (0), and the upper 
end of the scale has a value of one, reflecting the best imaginable health state (or perfect 
health, or similar description).  States worse than dead are possible and have a negative 
value.  HSVs reflect the relative preferences of respondents across different health states, 
whereby a health state description that is more (or less) desirable than others will have a 
value that is closer to (or further away from) one (1.00) than the comparison health states. 
Although the use of the QALY in the assessment of health benefits in economic evaluations 
continues to be a major source of contention1, 2, the QALY is widely used and is the 
recommended outcome measure in a number of policy settings3-6.  There are variations in 
the estimation of health state values and the major areas of uncertainty can be characterised 
in three broad methodological areas; what to value? (i.e. how to describe health states), how 
to elicit preferences (values)?, and from whom to elicit preferences (whose values)?  Here 
we are concerned with the first of these questions, when considering whether or not to name 
the disease or health condition in the health state description being valued. 
Empirical evidence suggests that values for the same health states can vary depending 
upon whether or not the underlying condition is ‘labelled’, i.e. made known to respondents7.  
While some studies provide evidence that including labels for particular conditions 
significantly reduces HSVs, others have found no effect, and the results vary between 
conditions7-11.  In a recent study7 the use of a label for cancer health states, compared to 
otherwise identical unlabelled health states, resulted in significantly lower HSVs for severe 
health states but did not affect valuations of milder states.  There are alternative normative 
arguments for and against the use of condition labels.  For example, the condition itself may 
have an effect on HRQoL that is unrelated to a generic health state description.  Here 
Brazier and colleagues (2012)12 have drawn attention to potentially different valuations when 
people have ‘some difficulty in taking a long walk’ when it is due to needing to be near a 
toilet or owing to psychological problems, versus having ‘some difficulty taking a long walk’ 
due to physical problems.  In this case, condition labels may result in more accurate HSUVs.  
Alternatively, respondents may be influenced by their own knowledge, experience or 
preconceptions about the condition, in which case it may be argued that HSUVs could be 
4 
 
distorted due to irrelevant or inaccurate factors. However, there is little empirical evidence to 
explain such differences in the values ascribed to labelled and unlabelled health states, and 
consensus has yet to be been reached about the extent to which condition labels influence 
HSVs.   
A number of condition-specific preference based measures (CSPBMs) have been 
developed13, for use as alternatives to, or in addition to generic PBMs (e.g. EQ-5D14, SF-
6D15).  Yet, even when using a CSPBM the current guidance suggests that until more is 
known about which condition labels affect HSVs, and why discrepancies occur, condition 
labels should be avoided12.  Given the apparent variability of labelling effects between 
conditions, further research has been recommended to investigate the impact of labels in 
studies valuing states for particular conditions7, 12.   
In this study, the development of a condition-specific PBM for multiple sclerosis (MS) 
provided an opportunity to investigate the impact of including a condition label on public 
valuations of health states for MS, a chronic condition with a wide variety of symptoms.  As 
far as we are aware, this study is the first to derive a full tariff of values for labelled and 
unlabelled versions of the same classification system. 
 
2. Methods 
Two surveys were undertaken to elicit preferences for MS health state descriptions.  One 
avoided any mention of MS (the unlabelled version of the survey, Survey 1), while the other 
explicitly stated that the health states described the impact of MS (the labelled version, 
Survey 2).  In order to ensure that the results of the two surveys are comparable, the same 
preference elicitation methods were used for both surveys, and the same approach used for 
descriptive statistics and statistical analyses, consistent with current methodological 
guidance16. 
The MS health states were described using the Multiple Sclerosis Impact Scale Eight 
Dimension (MSIS-8D) classification system17 (Figure 1), which was derived from the MSIS-
29 item patient reported outcome measure, a frequently used and well validated measure of 
health-related quality of life (HRQoL) in MS18, 19.   
< Insert Figure 1 > 
The development of the MSIS-8D classification system is described in detail elsewhere17.  
The measure comprises eight dimensions of importance to the HRQoL of people with MS: 
physical functioning, mobility, social activities, daily activities, fatigue, cognitive function, 
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emotional well-being and depression.  Each dimension is represented by one MSIS-29 item, 
and each item has four response levels: (1) not at all, (2) a little, (3) moderately and (4) 
extremely.  
The survey methods are described in more detail elsewhere20.  In summary, a sample of 169 
MSIS-8D health states was selected to reflect states that are likely to be experienced by 
people with MS at different levels of severity.  These health states were allocated to five 
severity groups according to the sum of their levels across dimensions (see Supplementary 
material).  Each respondent valued one set of five MSIS-8D health states, covering a range 
of condition severity - the survey design comprised 34 sets of five health states - plus the 
worst health state described by the MSIS-8D (the pits state).  Prior to preference elicitation 
respondents completed the MSIS-8D for their own health, ranked three MSIS-8D health 
states and completed a practice TTO task.  Preferences were elicited using an internet 
version of the Measurement and Valuation of Health (MVH) variant of the time trade-off 
(TTO) technique21, which asks respondents to state whether they would prefer ten years in 
the target health state or a shorter period of time (x) in perfect health.  The length of time 
spent in perfect health (x) is varied until the respondent is indifferent between the two 
options, and the HSV is calculated as x/10.  Cognitive testing and an online pilot study 
(n=50) were used prior to the full survey to ensure the online survey worked as intended.  
The MVH protocol for health state valuation, and the elicitation of preferences from a 
representative sample of the UK population, were applied here to be consistent with 
recommendations from the UK National Institute for Health and Care Excellence (NICE) on 
methods for economic evaluations3.    
The online surveys were programmed and hosted by Accent Marketing and Research Ltd 
(http://www.accent-mr.com/), with participants recruited from an existing internet panel held 
by Survey Sampling International (SSI), an experienced online panel provider with rigorous 
quality control procedures.  Each survey aimed to obtain data from 1700 respondents, in 
order to achieve 40-50 observations per health state.  Given an absence of guidance on 
sample size requirements for such studies, reference to the literature in this area indicated 
this target sample size was appropriate.  To ensure that the sample was representative of 
the UK general population, rigid minimum quotas were set for age group (in ten-year age 
bands), gender and socio-economic group.  Ethical approval for both surveys was obtained 
from the University of Exeter Medical School Research Ethics Committee.   
The labelling of MS health states (Survey 2) was informed by the approach taken in a similar 
previous study7.  The condition was mentioned in the introduction to the survey and in the 
health state descriptions that were used in the valuation tasks.  Respondents were provided 
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with information about the condition, based on the definition provided on the UK NHS 
Choices website (Figure 2)22 prior to completing the TTO questions.  A link to the MS pages 
of the NHS Choices website was also included.  Respondents to the labelled version of the 
survey were asked which, if any, sources of information about MS they used to assist them 
in completing the TTO tasks (used survey description, they already know about MS, looked 
up additional information).  One of the dimensions of the MSIS-8D specifically referred to 
‘your MS’.  In order to remove any mention of MS from the unlabelled version of the survey, 
the phrase ‘your MS’ was replaced with ‘your health’.  This amended wording was retained 
for the labelled version of the survey, but the description of the health state was preceded by 
the phrase ‘Due to having MS’. 
< Insert Figure 2 > 
The procedure for valuing states considered worse than being dead was consistent with the 
MVH approach. Prior to analysis, a monotonic transformation was applied to transform 
negative values onto a scale from 0 to -114.  Data was excluded from respondents who 
provided responses that appeared internally inconsistent or illogical, specifically those where 
respondents:  
i. gave the same value to all six health states (unless they valued all health states as 
equivalent to full health),  
ii. gave all states a value less than or equal to zero,  
iii. valued the pits state at least as highly as all other states,  
iv. gave the least severe state a lower value than all other states, or  
v. provided three or more inconsistent responses with a difference in HSV of at least 
0.1 i.e. they valued a dominated health state as better than a logically better 
alternative by the equivalent of one year in the TTO exercise.   
Analysis of the impact of adding an MS label to MSIS-8D health states was undertaken in 
two phases.  In the first phase, mean HSVs from the labelled and unlabelled versions of the 
MSIS-8D valuation survey were compared using two-sided t-tests, and comparisons made 
by severity group.  In addition, data from both surveys was combined into a single dataset 
and a regression model was estimated using the following specification (Rowen et al, 
2012)7: 
yij = α + f(β′Xλ∂)+ γqi + εij 
i = 1, 2, . . ., n: individual health states  
j = 1, 2, . . ., m: individual respondents 
yij: health state i valued by respondent j 
X: vector of dummy variables for each level λ of dimension ∂ of the classification 
system, where level λ = 1 acts as a baseline for each dimension; 
q: dummy variable for labelling effects 
εij: error term.  
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This model, using random effects and a generalised least squares structure in order to allow 
for multiple observations per respondent23, aims to determine whether inclusion of an MS 
label influenced HSVs when these were modelled using dimension-levels for each health 
state description.    Model performance was assessed using root mean squared error, R-
squared statistics and the Wald chi-squared test7. 
In the second phase of the analysis, random effects models were estimated to produce a full 
tariff of HSVs for the MSIS-8D descriptive system (i.e. CSPBM) from each version of the 
survey, as follows12: 
yij = f(β′Xλ∂) + εij   
In order to ensure comparability between models, the same model specification was used for 
both labelled and unlabelled data16.  Where a lower level of severity resulted in a greater 
decrement (higher negative coefficient) to the HSV than a higher level of severity, levels 
were merged and the analysis was re-run to ensure a consistent model24. 
Models were compared in terms of their performance and predictive ability, using the 
following criteria: 
i. the proportion of coefficients that are statistically significant; 
ii. the number of coefficients that are not consistent with the dimension levels; 
iii. mean absolute error (MAE); 
iv. proportion of health states with prediction errors > 0.05 and > 0.10;  
v. R-squared statistics. 
 
The size and significance of coefficients was compared to investigate differences in the 
weighting of individual dimensions and in the effect of moving between dimension-levels, 
and the ranges of HSVs predicted by the models were compared.  In order to simplify the 
comparison between the coefficients of the two models, a rule of thumb was applied such 
that any absolute difference less than 0.01 would be considered negligible.   
Financial support for this study was provided in part by the Multiple Sclerosis Society of 
Great Britain and Northern Ireland.  The funding agreement ensured the authors’ 
independence in designing the study, interpreting the data, writing, and publishing the report.   
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3. Results 
The unlabelled survey (Survey 1) was completed by 1702 respondents, and 1788 completed 
the labelled survey (Survey 2).  A slightly higher percentage of respondents were excluded 
from the labelled survey (8.2%) compared to the unlabelled survey (7.4%) due to 
inconsistent or illogical responses.  Most of the exclusions (>75%) were due to respondents 
valuing the pits (worst) state at least as highly as all other states.  Data from 1576 
respondents to the unlabelled survey and 1641 respondents to the labelled survey were 
included in the analysis.  The median number of observations per health state was 47 for the 
unlabelled survey and 49 for the labelled survey.   
Table 1 reports the demographic characteristics of participants compared to the UK 
population. Overall, the samples were reasonably representative of the UK population. 
Although the percentage of participants aged over 65 was similar to the general population, 
both samples included a higher proportion from the 66-75 year age band and fewer 
respondents aged over 75. A lower proportion of the samples was in employment or had no 
qualifications. There were no differences in the socio-demographic profiles of the two 
samples. 
< Insert Table 1 > 
The mean directly elicited values for each health state in the unlabelled survey ranged from 
0.08 for the pits state to 0.89 for the best health state described by the MSIS-8D, and from 
0.07 to 0.89 for the labelled survey (see Appendix 1).  Table 2 reports data on understanding 
of the TTO questions and participant level of ease or difficulty in making choices.  There was 
little difference between the labelled and unlabelled versions of the survey.  A large 
proportion of respondents (81.4%) reported that they used the description of MS that was 
provided in the survey.  Around one third (34.7%) reported that they “already knew quite a bit 
about MS”.  Only 6.1% reported that they had looked up additional information about MS.  
Completion times were similar across surveys with a mean completion time of 10 minutes 25 
seconds (sd: 8 mins 44 seconds). 
< Insert Table 2 > 
Table 3 reports comparison of mean HSVs, showing a significant difference in overall mean 
HSVs between the labelled and unlabelled versions of the survey.  The mean HSV was 
0.023 lower when the MS label was included in the health state descriptions.  Mean HSVs 
for the severity groups reflect the expected direction of preferences, with HSVs decreasing 
as severity increases.  The difference in means was statistically significant (p < 0.05) for two 
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severity groups: the mildest group (Group 1) and one of the moderate groups (Group 4).  At 
the 10% level, the difference between means was significant for the four mildest severity 
groups.  The differences between the means for the most severe group (Group 5) and for 
the pits state were not statistically significant.   
< Insert Table 3 > 
 
The results of the model estimated using data from both samples are presented in Table 4.  
Results broadly reflect the expected direction of preferences, with mean HSVs decreasing 
as severity increases.  The impact of the condition label is statistically significant, with a 
negative coefficient, indicating that the presence of an MS label lowers mean HSVs.  The p-
value for the Wald chi-squared test was <0.001 . 
< Insert Table 4 > 
Table 5 reports the sets of full CSPBM tariffs, across all described health states, estimated 
from the labelled and unlabelled datasets (i.e. MSIS-8D-unlabelled, and MSIS-8D-labelled).  
The coefficients of both models had the expected negative sign, i.e. as impairments in health 
status worsened for each dimension this has a negative effect on HSVs.  All model 
coefficients for the unlabelled version of the survey were consistent with expected 
preferences, coefficients increasing as the level of impairment increased, with lower HSVs 
for increased impairment on that dimension.  In the initial random effects model for the 
labelled version of the survey, three coefficients were inconsistent with the expected 
direction of preference.  Therefore, levels were merged to create a consistent model which 
was re-estimated using data from the labelled version of the survey by merging levels 2 and 
3 for the physical, social and emotion domains.   
Predicted HSVs ranged from 0.079 to 0.883 for the unlabelled version of the survey and 
from 0.066 to 0.861 for the labelled version.  The differences between the coefficients of the 
two models are illustrated in Figure 3. 
< Insert Table 5 > 
<Insert Figure 2> 
The addition of the MS label resulted in an increase in absolute coefficient sizes for five of 
the MSIS-8D dimensions; an increase in coefficient size indicates that moving from level 1 to 
the level corresponding to the coefficient has a greater negative impact on HSVs.  These 
were: Physical (coefficients for levels 2 and 3), Social (levels 2 and 4), Mobility (all levels), 
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Fatigue (level 3), and Cognition (levels 3 and 4).  The labelled version had a higher number 
of significant coefficients for the Mobility, Fatigue and Cognition dimensions. 
 
The addition of the MS label resulted in a reduction in absolute coefficient sizes for the 
remaining three dimensions; a decrease in coefficient size indicates that moving from level 1 
to the level corresponding to the coefficient has a smaller negative impact on HSVs.  These 
were: Daily activities (all levels), Emotion (levels 3 and 4), and Depression (levels 2 and 4).   
 
Table 5 also reports the effect of including an MS label on the distance between adjacent 
coefficients, reflecting the impact of moving between levels on each dimension of the MSIS-
8D, using the aforementioned rule of thumb (on differences >0.01).  This suggests a more 
complex scenario than was apparent from the overall effects on coefficient sizes.  For 
example, if we move from level 1 to level 2 on the Physical dimension, this has a larger 
impact on HSVs when modelled using labelled data, but moving from level 3 to level 4 on the 
same dimension has a larger impact when modelled using the unlabelled data.  Indeed, four 
of the eight MSIS-8D dimensions have a mix of larger and smaller single-level increments 
when the two models are compared (Physical, Social, Fatigue, Depression). 
 
When the condition was labelled more of the dimension coefficients were significant (n=14), 
compared to the model for the unlabelled data (n=11).  Conversely, inclusion of the MS label 
was detrimental to the performance and predictive ability of the estimated model, reducing 
the size of the within and overall R-squared statistics, slightly increasing the MAE and RMSE 
and producing a greater number of health states with prediction errors greater than 0.1 or 
0.05.  There was no difference between the Wald chi-squared p-values of the models. 
 
4. Discussion 
Results indicate that adding an MS label to descriptions of health states significantly reduces 
estimated overall mean health state values, compared with values elicited for otherwise 
identical unlabelled states.  Data from directly elicited HSVs suggests that the MS label had 
a more significant effect on values for less severe health states and no significant effect on 
values for the most severe states, reflecting a reversal of the findings reported by Rowen et 
al7, who found that including a cancer label had a more significant impact on severe states.     
However, this overall finding masks a more complex underlying pattern in the data, as the 
inclusion of the MS label had a differential impact across the dimensions of the MSIS-8D.  
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For mental health dimensions (depression and emotional well-being) and for daily activities, 
the impact of the condition label was to reduce the impact of impairments (increasing 
severity) on the HSVs, i.e. smaller decrements in the HSV when impairments present 
compared to unlabelled data.  Whereas the impact of the condition label on estimated HSVs 
of limitations in physical health dimensions (physical and mobility), social activities, fatigue 
and cognition was increased, i.e. greater decrements in the HSV when impairment present 
compared to unlabelled data.  The findings suggest interventions that target physical 
symptoms, social activities, fatigue and cognition may appear more effective (greater health 
gain if symptoms alleviated), and hence more cost-effective, if assessed using the labelled 
version of the MSIS-8D model, while interventions that improve mental and emotional 
wellbeing may appear less effective and cost-effective, compared to assessment with 
unlabelled data.   
An added level of complexity is introduced by the differences between the models in terms of 
the impact on HSVs of moving between individual levels within each dimension.  
Furthermore, the model based on labelled health state data was more sensitive to changes 
in moderate levels of some domains, with more significant coefficients at level 2 (mobility) 
and level 3 (mobility, fatigue and cognition). 
Findings suggest that the inclusion of a condition label, when estimating HSVs, may have 
important implications for the results of economic evaluations.  In a decision analytic context 
it is the difference (interval) between health state values (e.g. pre- and post- intervention) 
that are most relevant rather than absolute HSVs.  For example, if all labelled health states 
were valued 0.02 higher than all unlabelled health states, both sets of HSV data should 
produce identical values for any given change in health status and there would be no 
difference in the results of economic evaluations (assuming no impacts from mortality 
effects).  It is the difference in the relative weighting of dimensions and in the effect of 
changes in individual dimension-levels that is relevant in determining the effects of condition 
labels on the results of cost effectiveness analysis.  To illustrate, a shift from health state 
22323222 (level 3 on the mobility and fatigue dimensions, level 2 on all other dimensions) to 
health state 22222222 (level 2 on all dimensions) produces an improvement in HSV of 0.049 
(0.673 - 0.624) using the labelled version of the MSIS-8D tariff, compared to 0.021 (0.717 – 
0.696) using the unlabelled version.  Conversely, a shift from health state 22222322 (level 3 
on emotion, level 2 on all other dimensions) to health state 22222221 (level 1 on depression, 
level 2 on all other dimensions) produces an improvement of 0.016 (0.689 - 0.673) using the 
labelled version and of 0.053 (0.743 – 0.689) using the unlabelled version.   
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There was little difference in the performance or predictive ability of the two models.  The 
model based on labelled data had slightly lower predictive ability in terms of the R-squared 
statistics, MAE, RMSE and the number of health states with prediction errors greater than 
0.1 or 0.05.  This may be due to the increased cognitive demand placed on respondents to 
the labelled version of the study, who were asked to imagine that they had MS in addition to 
imagining themselves in particular health states. 
There are a number of limitations with the study.  In keeping with previous guidance3, 
valuation methods were consistent with the MVH version of the TTO protocol.  One 
consequence of this is that the protocol asks respondents to imagine remaining in a 
specified health state for ten years, with no changes in that health state during that time.  
However, the definition of MS that was provided for respondents to the labelled version of 
the survey stated that MS is usually characterised by alternating periods of relapse and 
remission, or by ongoing progression.  This may have caused confusion for respondents to 
the labelled version of the survey and may have affected the values they attributed to health 
states. This is a potential area for further research.   
Concerns have been raised about whether TTO tasks may pose too high a cognitive burden 
for online administration25. While recent evaluations of internet TTO have produced mixed 
results26-28, the nature of the preference data elicited here, alongside respondents’ self-
reported task comprehension, suggest that the TTO technique can be administered 
successfully online. 
A central limitation of this study is that it is quantitative in nature and therefore cannot explain 
why HSVs differ between labelled and unlabelled health states.  Reasons for the differences 
in the health state values require investigation using qualitative methods.  There are a 
number of possible mechanisms that may explain differences between values elicited for 
labelled and unlabelled health states.  It may be that differences arise due to a legitimate 
effect of the condition per se, for example contextual effects that provide differing 
explanations for impairments in functioning.  Alternatively, labelling health states may prompt 
respondents to take irrelevant or inaccurate factors into account, or lead to ‘focussing 
effects’, thereby distorting HSVs.  Use of a condition label may lead to respondents own 
preconceptions about the condition being overly prominent29, and/or increased influence of 
social attitudes24, and/or poor hedonic forecasting30.  Further research in this area is planned 
to explore how and why respondents’ cognitive processes differ when undertaking TTO 
tasks for labelled and unlabelled MSIS-8D health states.  This will also enable investigation 
of the suitability of the ten-year time-frame for a variable, progressive condition, as 
mentioned above. 
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To our knowledge, this is the first study to undertake two full-scale preference elicitation 
surveys for the same condition-specific classification system, using large, representative 
samples of the general population and a large sample of health states, in order to compare 
both observed and predicted values for labelled and unlabelled health states.  Results 
presented and discussed here show that including an MS label in health state descriptions 
reduces the overall estimated health state values associated with MSIS-8D health states and 
affects the relative importance of individual dimensions of HRQoL in influencing HSVs.   The 
differences reported here between health state values, by labelled versus unlabelled states, 
could be considered relatively small, in a descriptive context.  However, in economic 
evaluations mean HSVs and related QALY differences (between comparators) are often 
relatively small and we consider the findings here to be important, firstly in addressing an 
area of methodological uncertainty, but also for applied decision making contexts.  We 
acknowledge that it will only be in the consideration of any differences (in HSVs) in a 
decision-analytic context (policy, CUA setting) that we may see the magnitude of the impact 
of using condition labels to elicit preferences and to estimate HSVs, and this is the focus for 
ongoing and future research.   
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Figure 1: MSIS-8D classification system 
Physical subscale (includes all physical and social dimensions) 
Dimension MSIS-29 item Response levels 
Physical In the past two weeks, how much has your MS limited your ability to do physically demanding tasks? 1 2 3 4 
 In the past two weeks, how much have you been bothered by:     
Social Limitations in your social and leisure activities at home? 1 2 3 4 
Mobility Being stuck at home more than you would like to be? 1 2 3 4 
Daily activities Having to cut down the amount of time you spent on work or other daily activities? 1 2 3 4 
Psychological subscale (includes all psychological and other non-physical dimensions) 
Dimension MSIS-29 item Response levels 
 In the past two weeks, how much have you been bothered by:     
Cognition Feeling mentally fatigued? 1 2 3 4 
Emotion Feeling irritable, impatient or short-tempered? 1 2 3 4 
Cognition Problems concentrating? 1 2 3 4 
Depression Feeling depressed? 1 2 3 4 
Response levels: 1 = not at all; 2 = a little; 3 = moderately; 4 = extremely 
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Figure 2: Information about MS provided for respondents to the labelled survey 
In the following questions, we would like you to imagine that you have multiple sclerosis.  
Multiple sclerosis affects nerves in the brain and spinal cord, causing a wide range of 
symptoms including:  
 loss of vision – usually only in one eye  
 spasticity – muscle stiffness that can lead to uncontrolled muscle movements  
 ataxia – difficulties with balance and co-ordination  
 fatigue – feeling very tired during the day  
Around eight out of 10 people with multiple sclerosis (MS) are diagnosed with the relapsing 
remitting type of MS.  Someone with relapsing remitting MS will have flare-ups of symptoms, 
known as relapses. These can last from a few days to a few months.  These will be followed by 
periods where symptoms are mild or disappear altogether. This is known as remission and can 
last for days, weeks or sometimes months. 
Usually after around 15 years, around half of people with relapsing remitting MS will go on to 
develop secondary progressive MS.  In secondary progressive MS, symptoms gradually 
worsen over time. Some people may still have relapses, but without full recovery from 
symptoms. 
The least common form of MS is primary progressive MS. In this type, symptoms gradually get 
worse over time and there are no periods of remission. 
Taken from the NHS Choices website, see:  
http://www.nhs.uk/conditions/Multiple-sclerosis/Pages/Introduction.aspx 
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Figure 3: Comparing the size of coefficients by dimension and level for the valuation models of labelled and unlabelled health state 
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Table 1: Characteristics of respondents 
 
Unlabelled survey 
(n=1576) 
Labelled survey 
(n = 1641) UK 
Nationality  
England 1378 87.44% 1387 84.52% 83.84%
Northern Ireland 23 1.46% 29 1.77% 2.77%
Scotland 117 7.42% 125 7.62% 8.52%
Wales 58 3.68% 100 6.09% 4.87%
English region (n = 1387)  
East Midlands 100 7.26% 119 8.58% 8.58%
East of England 135 9.80% 144 10.38% 11.03%
Greater London 173 12.55% 153 11.03% 15.34%
North East England 73 5.30% 76 5.48% 4.94%
North West England 192 13.93% 189 13.63% 13.26%
South East England 276 20.03% 269 19.39% 16.28%
South West England 154 11.18% 166 11.97% 10.16%
West Midlands 138 10.01% 115 8.29% 10.45%
Yorkshire and the Humber 137 9.94% 156 11.25% 9.94%
Gender  
Female 829 52.60% 865 52.71% 51.40%
Male 747 47.40% 776 47.29% 48.60%
Age group  
18-25 206 13.07% 197 12.00% 13.56%
26-35 269 17.07% 278 16.94% 16.88%
36-45 261 16.56% 256 15.60% 17.48%
46-55 279 17.70% 297 18.10% 17.45%
56-65 253 16.05% 293 17.85% 14.69%
66-75 279 17.70% 285 17.37% 10.83%
76-85 26 1.65% 35 2.13% 6.69%
86 or over 3 0.19% 0 0.00% 2.41%
Employment status  
Employed 801 50.82% 817 49.79% 60.05%
Economically inactive 681 43.21% 738 44.97% 35.50%
Unemployed/ seeking work 89 5.65% 76 4.63% 4.45%
Other/ Prefer not to say 5 0.32% 10 0.61% 
Highest level of education  
Level 4 472 29.95% 497 30.29% 27.02%
Level 3 459 29.12% 517 31.51% 12.12%
Level 1 or 2 443 28.11% 435 26.51% 29.24%
Trade apprenticeships 61 3.87% 60 3.66% 3.30%
Other qualifications 46 2.92% 51 3.11% 5.13%
No qualifications 89 5.65% 78 4.75% 23.19%
Prefer not to say 6 0.38% 3 0.18% 
Socio-economic group  
AB 422 26.78% 462 28.15% 25%
C1 495 31.41% 469 28.58% 29%
C2 295 18.72% 350 21.33% 21%
DE 364 23.10% 360 21.94% 25%
Sources for UK data: 
Nationality, region, gender and age group: ONS mid-2012 population estimates, age 18 and over 
Employment status: ONS labour market statistics, August to December 2013, age 18 and over 
Educational attainment: 2011 UK Census, age 16 and over 
Socio-economic group: provided by Accent Marketing and Research Ltd 
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Table 2: Self-reported task comprehension 
What were the questions like to understand? How easy or difficult was it to make choices? 
 Unlabelled Labelled Unlabelled Labelled 
Very easy 617 39.15% 676 41.19% Very easy 250 15.86% 288 17.55%
Easy 825 52.35% 816 49.73% Easy 583 36.99% 538 32.78%
Difficult 126 7.99% 137 8.35% Difficult 668 42.39% 702 42.78%
Very difficult 8 0.51% 12 0.73% Very difficult 75 4.76% 113 6.89%
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Table 3: Comparison between labelled and unlabelled data, by severity group  
Unlabelled Labelled Difference t stat Pr(T > t)
All health states Mean HSV 0.484 0.461 0.023 3.397 0.0007
 SD 0.0048 0.0049  
Severity Group 1 Mean HSV 0.8173 0.7803 0.0370 4.1528 <0.0001
(least severe) SD 0.2330 0.2697
Severity Group 2 Mean HSV 0.6818 0.6654 0.0164 1.4143 0.0787
SD 0.3193 0.3364
Severity Group 3 Mean HSV 0.5782 0.5586 0.0196 1.4314 0.0762
SD 0.3830 0.3939
Severity Group 4 Mean HSV 0.4733 0.4393 0.0340 2.1983 0.0140
SD 0.4213 0.4540
Severity Group 5 Mean HSV 0.2693 0.2483 0.0210 1.2038 0.1144
SD 0.4828 0.5042
Pits health state Mean HSV 0.0830 0.0715 0.0115 0.6676 0.2522
SD 0.4800 0.4937
Number of observations in each severity group (and for the pits state): unlabelled = 1576; labelled = 
1641; combined = 3217. Degrees of freedom = 3215. SD = standard deviation 
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Table 4: Results of initial regression analysis 
 Dimension and level Coefficient   P>z
Physical 2 -0.062 0.000
 3 -0.064 0.000
 4 -0.164 0.000
Social 2 -0.009 0.431
 3 -0.014 0.423
 4 -0.073 0.000
Mobility 2 -0.027 0.020
 3 -0.053 0.002
 4 -0.101 0.000
Daily activities 2 -0.013 0.275
3 -0.028 0.094
4 -0.065 0.001
Fatigue 2 -0.024 0.021
 3 -0.035 0.026
 4 -0.079 0.000
Emotion 2 -0.011 0.285
 3 -0.021 0.174
 4 -0.062 0.003
Cognition 2 -0.011 0.321
 3 -0.041 0.012
 4 -0.107 0.000
Depression 2 -0.021 0.060
 3 -0.073 0.000
 4 -0.147 0.000
MS label -0.024 0.033
Constant 0.884 0.000
Performance 
sigma_u 0.293
sigma_e 0.277
rho 0.529
RMSE 0.277
R-squared 
  within 0.496
  between 0.010
  overall 0.282
Wald chi2 15825.34
Prob chi2 <0.001
Observations = 19302; groups = 3217 
Base case: Dimension Level 1, unlabelled 
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 Table 5: Impact of MS label on estimated HSV tariffs for MSIS-8D 
Dimension Level 
Model coefficients Impact of moving between levels 
Unlabelled Labelled Diff Unlabelled Labelled Diff
Physical 2 -0.052** -0.071**
+0.019 1 to 2 0.052 0.071 +0.019
 3 -0.059* +0.012 2 to 3 0.007 0.000 -0.007
 4 -0.170** -0.162** -0.008 3 to 4 0.111 0.091 -0.020
Social 2 -0.002 -0.014
+0.012 1 to 2 0.002 0.014 +0.012
 3 -0.012 +0.002 2 to 3 0.010 0.000 -0.010
 4 -0.063* -0.081** +0.018 3 to 4 0.051 0.067 +0.016
Mobility 2 -0.020 -0.031* +0.011 1 to 2 0.020 0.031 +0.011
 3 -0.038 -0.066** +0.028 2 to 3 0.018 0.035 +0.017
 4 -0.086** -0.116** +0.030 3 to 4 0.048 0.049 +0.001
Daily 
activities 
2 -0.023 -0.004 -0.019 1 to 2 0.023 0.004 -0.019
3 -0.038 -0.020 -0.018 2 to 3 0.015 0.015 +0.001
 4 -0.077** -0.053* -0.025 3 to 4 0.040 0.033 -0.007
Fatigue 2 -0.022 -0.027 +0.005 1 to 2 0.022 0.027 +0.005
 3 -0.025 -0.040* +0.015 2 to 3 0.003 0.014 +0.011
 4 -0.077** -0.076** -0.002 3 to 4 0.052 0.035 -0.017
Emotion 2 -0.009 -0.014
+0.004 1 to 2 0.009 0.014 +0.004
 3 -0.037 -0.023 2 to 3 0.027 0.000 -0.027
 4 -0.081** -0.051* -0.030 3 to 4 0.044 0.037 -0.007
Cognition 2 -0.011 -0.011 0.000 1 to 2 0.011 0.011 0.000
 3 -0.032 -0.046* +0.015 2 to 3 0.021 0.035 +0.014
 4 -0.090** -0.119** +0.029 3 to 4 0.058 0.073 +0.015
Depression 2 -0.026 -0.016 -0.010 1 to 2 0.026 0.016 -0.010
 3 -0.071** -0.075** +0.004 2 to 3 0.045 0.059 +0.014
 4 -0.158** -0.137** -0.021 3 to 4 0.087 0.062 -0.025
Constant 0.883** 0.861** -0.022   
Model performance Unlabelled Labelled
Coefficients: 24 21
  significant (p<0.05) 45.83% (11) 66.67% (14)
  significant (p<0.1) 45.83% (11) 71.43% (15)
R-squared: within 0.5028 0.4894
 between 0.0068 0.0109
 overall 0.2953 0.2688
Wald chi2 (prob > chi2) 7959.82 (<0.001) 7864.32 (<0.001)
RMSE 0.276 0.278
MAE 0.041 0.044
Errors > 0.1 9 (5.33%) 11 (6.51%)
Errors > 0.05 49 (28.99%) 65 (38.46%)
Range of HSVs 0.079 to 0.883 0.066 to 0.861
Observations (groups) 9456 (1576) 9846 (1641)
* p<0.05; **p<0.01. Levels 2 and 3 were merged in the labelled version for Physical, Social and Emotion 
Diff = difference:  
+ indicates that the MS label increased the size of the coefficient or the impact of moving between levels 
- indicates that the MS label reduced the size of the coefficient or the impact of moving between levels 
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Appendix 1: Mean (SD) for directly elicited health state values 
 Unlabelled survey Labelled survey 
Health state Mean HSV SD Obs Mean HSV SD Obs 
11111111 0.893 0.177 50 0.893 0.260 40 
11111112 0.870 0.179 51 0.826 0.222 46 
11111121 0.872 0.231 45 0.846 0.266 50 
11111211 0.855 0.209 93 0.825 0.246 93 
11112111 0.905 0.169 47 0.825 0.260 41 
11121111 0.872 0.202 38 0.825 0.265 67 
11211111 0.848 0.209 43 0.871 0.195 57 
12111111 0.873 0.221 53 0.818 0.239 48 
21111111 0.829 0.259 96 0.794 0.286 90 
11112211 0.868 0.195 47 0.852 0.227 50 
21112111 0.743 0.260 44 0.764 0.251 50 
21121111 0.845 0.199 46 0.825 0.216 50 
11112221 0.876 0.234 51 0.808 0.210 49 
21112211 0.808 0.214 47 0.713 0.337 41 
21122111 0.788 0.241 49 0.748 0.285 50 
22121111 0.852 0.206 38 0.779 0.231 58 
11112222 0.783 0.226 49 0.775 0.249 49 
21112221 0.827 0.174 37 0.720 0.400 49 
21122211 0.822 0.250 49 0.796 0.245 50 
22122111 0.810 0.210 50 0.735 0.299 62 
32121111 0.839 0.239 44 0.756 0.266 51 
11113222 0.787 0.231 55 0.763 0.247 51 
21112222 0.720 0.249 50 0.773 0.244 46 
21122221 0.733 0.260 41 0.777 0.296 46 
22122211 0.733 0.284 40 0.766 0.244 45 
32122111 0.796 0.230 50 0.769 0.273 40 
32221111 0.816 0.244 45 0.726 0.310 43 
11113322 0.799 0.214 51 0.794 0.240 50 
21113222 0.748 0.228 39 0.722 0.252 52 
21122222 0.739 0.299 49 0.715 0.289 40 
22122221 0.705 0.246 41 0.733 0.380 46 
32122211 0.751 0.333 41 0.614 0.275 43 
32222111 0.782 0.188 48 0.656 0.336 44 
42221111 0.612 0.282 43 0.632 0.352 49 
11113332 0.777 0.218 37 0.762 0.289 49 
21113322 0.744 0.279 47 0.715 0.295 50 
21123222 0.759 0.332 38 0.718 0.300 67 
22122222 0.671 0.332 40 0.772 0.237 45 
32122221 0.762 0.225 43 0.804 0.226 57 
32222211 0.727 0.266 50 0.762 0.293 40 
42222111 0.649 0.348 39 0.725 0.237 52 
42231111 0.628 0.383 49 0.657 0.384 50 
11114332 0.769 0.286 47 0.627 0.332 41 
21113332 0.694 0.290 52 0.654 0.387 39 
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 Unlabelled survey Labelled survey 
Health state Mean HSV SD Obs Mean HSV SD Obs 
21123322 0.751 0.339 44 0.642 0.368 51 
22123222 0.721 0.288 50 0.708 0.245 62 
32122222 0.755 0.294 49 0.748 0.208 50 
32222221 0.722 0.338 51 0.752 0.235 49 
42222211 0.638 0.401 53 0.601 0.378 48 
42232111 0.650 0.279 49 0.634 0.353 49 
42331111 0.589 0.384 50 0.620 0.381 40 
11114333 0.706 0.245 41 0.560 0.407 43 
21114332 0.612 0.379 44 0.609 0.417 50 
21123332 0.636 0.401 45 0.680 0.261 50 
22123322 0.741 0.268 51 0.667 0.301 46 
32123222 0.730 0.248 46 0.727 0.326 50 
32222222 0.647 0.319 49 0.686 0.312 40 
42222221 0.720 0.279 38 0.571 0.403 58 
42232211 0.650 0.375 45 0.646 0.356 43 
42332111 0.611 0.383 51 0.559 0.443 50 
43331111 0.542 0.431 50 0.600 0.396 44 
21114333 0.595 0.324 43 0.576 0.347 49 
21124332 0.688 0.200 48 0.561 0.303 44 
22123332 0.690 0.242 50 0.683 0.306 46 
32123322 0.693 0.228 44 0.648 0.334 51 
32223222 0.723 0.244 55 0.718 0.285 51 
42222222 0.505 0.431 41 0.611 0.381 46 
42232221 0.616 0.416 55 0.511 0.383 51 
42332211 0.652 0.250 48 0.514 0.371 44 
43332111 0.580 0.334 45 0.516 0.459 50 
43341111 0.640 0.274 47 0.594 0.317 41 
21124333 0.610 0.363 43 0.668 0.348 57 
22124332 0.615 0.313 46 0.685 0.338 50 
32123332 0.620 0.444 41 0.588 0.357 43 
32223322 0.702 0.285 38 0.653 0.343 67 
42223222 0.664 0.299 49 0.600 0.329 50 
42232222 0.661 0.307 47 0.621 0.339 50 
42332221 0.563 0.417 50 0.589 0.397 40 
43332211 0.577 0.401 49 0.531 0.420 40 
43342111 0.500 0.436 53 0.510 0.427 48 
43441111 0.529 0.387 50 0.482 0.408 44 
21124343 0.450 0.455 52 0.479 0.474 39 
22124333 0.500 0.449 44 0.539 0.415 50 
32124332 0.688 0.401 51 0.631 0.288 49 
32223332 0.754 0.247 44 0.596 0.350 51 
42223322 0.552 0.355 45 0.598 0.337 43 
42233222 0.543 0.384 44 0.524 0.402 51 
42332222 0.576 0.355 37 0.448 0.536 49 
43332221 0.637 0.334 47 0.470 0.441 41 
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 Unlabelled survey Labelled survey 
Health state Mean HSV SD Obs Mean HSV SD Obs 
43342211 0.543 0.433 49 0.532 0.465 50 
43442111 0.520 0.402 51 0.423 0.490 46 
44441111 0.622 0.356 47 0.379 0.452 41 
22124343 0.510 0.461 49 0.458 0.514 50 
32124333 0.553 0.345 50 0.598 0.425 40 
32224332 0.530 0.421 40 0.667 0.274 45 
42223332 0.514 0.372 45 0.474 0.388 50 
42233322 0.521 0.416 39 0.595 0.319 52 
42333222 0.526 0.404 51 0.538 0.409 50 
43332222 0.564 0.391 50 0.603 0.323 62 
43342221 0.449 0.511 49 0.580 0.343 49 
43442211 0.596 0.364 38 0.422 0.424 58 
44442111 0.467 0.437 50 0.392 0.422 46 
32124343 0.506 0.430 39 0.564 0.364 52 
32224333 0.604 0.356 50 0.473 0.470 44 
42224332 0.455 0.410 47 0.438 0.409 41 
42233332 0.565 0.330 50 0.535 0.356 62 
42333322 0.606 0.438 51 0.553 0.363 49 
43333222 0.532 0.417 41 0.425 0.451 43 
43342222 0.644 0.311 47 0.437 0.468 50 
43442221 0.441 0.467 50 0.586 0.332 40 
44442211 0.381 0.504 50 0.374 0.542 40 
32224343 0.572 0.254 38 0.454 0.405 58 
42224333 0.442 0.404 51 0.399 0.469 46 
42234332 0.452 0.446 49 0.489 0.415 40 
42333332 0.580 0.378 49 0.527 0.392 50 
43333322 0.410 0.419 41 0.590 0.385 46 
43343222 0.616 0.332 47 0.313 0.501 41 
43442222 0.484 0.364 44 0.448 0.434 51 
44442221 0.337 0.479 40 0.456 0.415 45 
32224443 0.407 0.457 55 0.391 0.459 51 
42224343 0.456 0.363 48 0.317 0.470 44 
42234333 0.435 0.427 46 0.478 0.446 50 
42334332 0.418 0.388 43 0.485 0.437 49 
43333332 0.479 0.450 45 0.438 0.471 43 
43343322 0.417 0.509 44 0.436 0.430 50 
43443222 0.447 0.359 50 0.449 0.443 46 
44442222 0.380 0.478 52 0.320 0.585 39 
32224444 0.351 0.487 53 0.282 0.513 48 
42224443 0.347 0.385 37 0.230 0.508 49 
42234343 0.493 0.445 44 0.322 0.462 51 
42334333 0.440 0.419 49 0.426 0.463 49 
43334332 0.479 0.422 51 0.477 0.465 50 
43343332 0.512 0.411 43 0.564 0.509 57 
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 Unlabelled survey Labelled survey 
Health state Mean HSV SD Obs Mean HSV SD Obs 
43443322 0.505 0.480 43 0.565 0.434 57 
44443222 0.353 0.467 38 0.301 0.480 67 
42224444 0.272 0.540 51 0.266 0.585 50 
42234443 0.255 0.456 44 0.298 0.451 50 
42334343 0.341 0.487 50 0.393 0.482 40 
43334333 0.391 0.427 52 0.370 0.538 39 
43344332 0.445 0.405 51 0.394 0.502 46 
43443332 0.492 0.492 44 0.360 0.461 51 
44443322 0.417 0.429 46 0.475 0.444 50 
42234444 0.098 0.525 55 0.190 0.515 51 
42334443 0.328 0.367 37 0.204 0.510 49 
43334343 0.349 0.480 53 0.260 0.478 48 
43344333 0.416 0.352 48 0.280 0.476 44 
43444332 0.389 0.453 45 0.410 0.433 43 
44443332 0.436 0.394 47 0.203 0.520 41 
42334444 0.228 0.520 38 0.125 0.497 67 
43334443 0.230 0.516 41 0.404 0.474 46 
43344343 0.316 0.472 45 0.333 0.488 50 
43444333 0.290 0.515 41 0.181 0.514 43 
44444332 0.299 0.509 39 0.322 0.484 52 
43334444 0.230 0.534 49 0.195 0.525 50 
43344443 0.216 0.390 50 0.273 0.565 40 
43444343 0.242 0.471 47 0.168 0.485 41 
44444333 0.189 0.505 40 0.327 0.523 45 
43344444 0.165 0.434 50 0.190 0.479 46 
43444443 0.284 0.476 50 0.203 0.528 44 
44444343 0.239 0.514 47 0.257 0.492 50 
34444444 0.208 0.467 38 0.084 0.474 58 
43444444 0.059 0.465 43 0.124 0.371 49 
44344444 0.133 0.510 49 0.119 0.510 40 
44434444 0.193 0.485 50 0.135 0.487 62 
44443444 0.140 0.534 51 0.175 0.514 49 
44444344 0.136 0.477 49 0.039 0.512 50 
44444434 0.097 0.387 44 0.194 0.482 51 
44444443 0.150 0.529 49 0.018 0.530 49 
44444444 0.083 0.480 1576 0.072 0.494 1641 
 
 
 
